Erica D Warlick1, Celalettin Ustun2, Astrid Andreescu3, Anthony F Bonagura4, Andrew Brunner5, Abhinav B Chandra6, James M Foran7, Mark B Juckett8, Tamila L Kindwall-Keller9, Virginia M Klimek10, Daniel F Pease11, David P Steensma12, Bryce M Waldman13, Mary M Horowitz13,14, Linda J Burns13, Nandita Khera15. 1. Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota. 2. Rush University Medical Center, Chicago, Illinois. 3. Northern Light Eastern Maine Medical Center, Lafayette Family Cancer Institute, Bangor, Maine. 4. Optum, North Wales, Pennsylvania. 5. Massachusetts General Hospital, Boston, Massachusetts. 6. Yuma Regional Medical Center, Yuma, Arizona. 7. Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, Florida. 8. School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin. 9. University of Virginia, Charlottesville, Virginia. 10. Memorial Sloan Kettering Cancer Center, New York, New York. 11. Hennepin Healthcare, Minneapolis, Minnesota. 12. Dana-Farber Cancer Institute, Boston, Massachusetts. 13. Center for International Blood and Marrow Transplant, Milwaukee, Wisconsin. 14. Medical College of Wisconsin, Milwaukee, Wisconsin. 15. College of Medicine, Mayo Clinic, Phoenix, Arizona.
Abstract
LAY SUMMARY: People who have advanced myelodysplastic syndromes (MDS) may live longer if they get a bone marrow transplant (BMT) instead of other therapies. However, only 15% of people with MDS actually get BMT. Experts say community physicians and transplant physicians should team up with insurance companies and patient advocacy groups to 1) spread this news about lifesaving advances in BMT, 2) ensure that everyone can afford health care, 3) provide emotional support for patients and families, 4) help patients and families get transportation and housing if they need to travel for transplant, and 5) improve care for people of under-represented racial and ethnic backgrounds.
LAY SUMMARY: People who have advanced myelodysplastic syndromes (MDS) may live longer if they get a bone marrow transplant (BMT) instead of other therapies. However, only 15% of people with MDS actually get BMT. Experts say community physicians and transplant physicians should team up with insurance companies and patient advocacy groups to 1) spread this news about lifesaving advances in BMT, 2) ensure that everyone can afford health care, 3) provide emotional support for patients and families, 4) help patients and families get transportation and housing if they need to travel for transplant, and 5) improve care for people of under-represented racial and ethnic backgrounds.
Authors: Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase Journal: Blood Date: 2012-06-27 Impact factor: 22.113
Authors: Thomas V Joshua; J Douglas Rizzo; Mei-Jie Zhang; Parameswaran N Hari; Seira Kurian; Marcelo Pasquini; Navneet S Majhail; Stephanie J Lee; Mary M Horowitz Journal: Cancer Date: 2010-07-15 Impact factor: 6.860
Authors: Teresa L Simoneau; Susan K Mikulich-Gilbertson; Crystal Natvig; Kristin Kilbourn; Janet Spradley; Rachel Grzywa-Cobb; Samuel Philips; Peter McSweeney; Mark L Laudenslager Journal: Psychooncology Date: 2013-02-25 Impact factor: 3.894
Authors: Christopher R Cogle; Sandra E Kurtin; Tanya G K Bentley; Michael S Broder; Eunice Chang; Scott Megaffin; Steven Fruchtman; Michael E Petrone; Sudipto Mukherjee Journal: Oncologist Date: 2017-03-10
Authors: James L Gajewski; Mary Foote; John Tietjen; Ben Melson; Angela Simmons; Richard E Champlin Journal: Biol Blood Marrow Transplant Date: 2004-07 Impact factor: 5.742